Characterization and validation of a chronic retinal neovascularization rabbit model by evaluating the efficacy of anti-angiogenic and anti-inflammatory drugs.

Autor:	Kumar S; Department of Ophthalmology, Absorption Systems: a Pharmaron company, 7901 Vickers St, San Diego, CA 92111, USA., Quach J; Department of Ophthalmology, Absorption Systems: a Pharmaron company, 7901 Vickers St, San Diego, CA 92111, USA., Cook N; Department of Ophthalmology, Absorption Systems: a Pharmaron company, 7901 Vickers St, San Diego, CA 92111, USA., Gum G; Department of Ophthalmology, Absorption Systems: a Pharmaron company, 7901 Vickers St, San Diego, CA 92111, USA., Naageshwaran V; Department of Ophthalmology, Absorption Systems: a Pharmaron company, 7901 Vickers St, San Diego, CA 92111, USA.
Jazyk:	angličtina
Zdroj:	International journal of ophthalmology [Int J Ophthalmol] 2022 Jan 18; Vol. 15 (1), pp. 15-22. Date of Electronic Publication: 2022 Jan 18 (Print Publication: 2022).
DOI:	10.18240/ijo.2022.01.03
Abstrakt:	Aim: To establish a rabbit model with chronic condition of retinal neovascularization (RNV) induced by intravitreal (IVT) injection of DL-2-aminoadipic acid (DL-AAA), a retinal glial (Müller) cell toxin, extensive characterization of DL-AAA induced angiographic features and the suitability of the model to evaluate anti-angiogenic and anti-inflammatory therapies for ocular vascular diseases. Methods: DL-AAA (80 mmol/L) was administered IVT into both eyes of Dutch Belted rabbit. Post DL-AAA delivery, clinical ophthalmic examinations were performed weekly following modified McDonald-Shadduck Scoring System. Color fundus photography, fluorescein angiography (FA), and optical coherence tomography (OCT) procedures were performed every 2 or 4wk until stable retinal vascular leakage was observed. Once stable retinal leakage (12wk post DL-AAA administration) was established, anti-vascular endothelial growth factor (VEGF) (bevacizumab, ranibizumab and aflibercept) and anti-inflammatory (triamcinolone, TAA) drugs were tested for their efficacy after IVT administration. Fluorescein angiograms were scored before and after treatment following a novel grading system, developed for the DL-AAA rabbit model. Results: Post DL-AAA administration, eyes were presented with moderate to severe retinal/choroidal inflammation which was accompanied by intense vitreous flare and presence of inflammatory cells in the vitreous humor. Retinal hemorrhage was restricted to the tips of neo-retinal vessels. FA revealed maximum retinal vascular leakage at 2wk after DL-AAA injection and then persisted as evidenced by stable mean FA scores in weeks 8 and 12. Retinal vascular angiographic and tomographic features were stable and consistent up to 36mo among two different staggers induced for RNV at two different occasions. Day 7, mean FA scores showed that 1 µg/eye of bevacizumab, ranibizumab, aflibercept and 2 µg/eye of TAA suppress 65%, 90%, 100% and 50% retinal vascular leakage, respectively. Day 30, bevacizumab and TAA continued to show 66% and 44% suppression while ranibizumab effect was becoming less effective (68%). In contrast, aflibercept was still able to fully (100%) suppress vascular leakage on day 30. On day 60, bevacizumab, ranibizumab and TAA showed suppression of 7%, 12%, and 9% retinal vascular leakage, respectively, however, aflibercept continued to be more effective showing 50% suppression of vascular leakage. Conclusion: The DL-AAA rabbit model mimics RNV angiographic features like RNV and chronic retinal leakage. Based on these features the DL-AAA rabbit model provides an invaluable tool that could be used to test the therapeutic efficacy and duration of action of novel anti-angiogenic formulations, alone or in combination with anti-inflammatory compounds. (International Journal of Ophthalmology Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu